1. Introduction
1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
4. US Prostate Cancer Nuclear Medicine Diagnostics Market Landscape
4.1 Market Overview
4.2 Porter's Five Forces Analysis
- 4.2.1 Bargaining Power of Suppliers
- 4.2.2 Bargaining Power of Buyers
- 4.2.3 Threat of New Entrants
- 4.2.4 Competitive Rivalry
- 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
- 4.3.1 Raw Material Suppliers
- 4.3.2 Manufacturers
- 4.3.3 Distributors/Suppliers
- 4.3.4 End Users
5. US Prostate Cancer Nuclear Medicine Diagnostics Market – Key Market Dynamics
5.1 Growth Drivers
- 5.1.1
- 5.1.2 Increasing prevalence of prostate cancer globally
- 5.1.3 Rising geriatric population
- 5.1.4 Technological advancements in nuclear medicine
- 5.1.5 Growing awareness about early diagnosis and treatment
- 5.1.6 Favorable reimbursement scenarios
- 5.1.7 Increasing adoption of advanced imaging techniques
- 5.1.8 Rising demand for precise and non-invasive diagnostic tools
- 5.1.9 Growing focus on personalized medicine
5.2 Market Opportunities
- 5.2.1
- 5.2.2 Launch of innovative nuclear medicine diagnostic products
- 5.2.3 Strategic partnerships and collaborations
- 5.2.4 Expansion into emerging markets
- 5.2.5 Development of advanced imaging techniques
- 5.2.6 Increasing focus on precision medicine
- 5.2.7 Growing demand for personalized treatment plans
- 5.2.8 Development of new radiopharmaceuticals
- 5.2.9 Clinical trials and research initiatives
5.3 Future Trends
- 5.3.1
- 5.3.2 Increasing adoption of PSMA-targeted imaging agents
- 5.3.3 Growing demand for personalized and precision medicine in prostate cancer
- 5.3.4 Advancements in radiolabeled therapies for targeted treatment
- 5.3.5 Expansion of PET/CT and PET/MRI imaging technologies
- 5.3.6 Rise in the use of liquid biopsy techniques for prostate cancer detection
- 5.3.7 Integration of artificial intelligence in nuclear imaging for enhanced diagnosis
- 5.3.8 Surge in clinical trials exploring new radiopharmaceuticals
- 5.3.9 Enhanced focus on early detection and recurrence monitoring
- 5.3.10 Improving reimbursement policies for nuclear medicine procedures
- 5.3.11 Increasing collaboration between pharmaceutical and diagnostic companies.
5.4 Impact of Drivers and Restraints
6. US Prostate Cancer Nuclear Medicine Diagnostics Market Regional Analysis
6.1 US Prostate Cancer Nuclear Medicine Diagnostics Market Overview
6.2 US Prostate Cancer Nuclear Medicine Diagnostics Market Revenue 2017-2027 (US$ Million)
6.3 US Prostate Cancer Nuclear Medicine Diagnostics Market Forecast Analysis
7. US Prostate Cancer Nuclear Medicine Diagnostics Market Analysis – by Type
7.1 SPECT
- 7.1.1 Overview
- 7.1.2 SPECT: US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2031 (US$ Million)
7.2 PET
- 7.2.1 Overview
- 7.2.2 PET: US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2031 (US$ Million)
8. US Prostate Cancer Nuclear Medicine Diagnostics Market Analysis – by PET Product
8.1 F-18
- 8.1.1 Overview
- 8.1.2 F-18: US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2027 (US$ Million)
8.2 C11
- 8.2.1 Overview
- 8.2.2 C11: US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2027 (US$ Million)
8.3 GA 68 PSMA
- 8.3.1 Overview
- 8.3.2 GA 68 PSMA : US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2027 (US$ Million)
9. US Prostate Cancer Nuclear Medicine Diagnostics Market – United States Analysis
9.1 United States
- 9.1.1 US Prostate Cancer Nuclear Medicine Diagnostics Market Breakdown, by Key
Country, 2020 and 2027 (%)
- 9.1.1.1 US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and
Forecast Analysis – by Country
- 9.1.1.1 United States :
US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2027 (US$ Million)
- 9.1.1.1.1 United States : US Prostate Cancer Nuclear Medicine Diagnostics Market Breakdown, by Type
- 9.1.1.1.2 United States : US Prostate Cancer Nuclear Medicine Diagnostics Market Breakdown, by PET Product
10. Competitive Landscape
10.1 Heat Map Analysis
10.2 Company Positioning and Concentration
11. US Prostate Cancer Nuclear Medicine Diagnostics Market Industry Landscape
11.1 Overview
11.2 Mergers and Acquisitions
11.3 Agreements, Collaborations, and Joint Ventures
11.4 New Product Launches
11.5 Expansions and Other Strategic Developments
12. Company Profiles
12.1 Blue Earth Diagnostics Limited
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Progenics Pharmaceuticals, Inc.
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 CURIUM
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Telix Pharmaceuticals Ltd.
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 NCM-USA LLC
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 ABX Advanced Biochemical Compounds GmbH
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Jubilant Radiopharma
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Lantheus Medical Imaging, Inc.
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Advanced Accelerator Applications (Novartis AG)
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Theragnostics
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
13. Appendix
13.1 About Business Market Insights
Get Free Sample For US Prostate Cancer Nuclear Medicine Diagnostics Market
